Relevant Essential Requirements under the UK MDR 2002

1. Key takeaways

The United Kingdom has retained the directive-era terminology — relevant essential requirements — rather than the General Safety and Performance Requirements (GSPR) of the EU MDR. For general devices, the essential requirements appear in regulation 8 together with the annexes it invokes; for active implantable devices, in regulation 22; and for IVDs, in regulation 34. The essential requirements are the substantive gate of United Kingdom device compliance: the declaration of conformity, the technical documentation and every conformity assessment procedure are all organised around demonstrating conformity with them. Treating them as a renamed version of the EU MDR requirements is the root cause of many failed documentation reviews, because the clause structures and some of the wording differ in ways that a superficial translation will not absorb.

2. Legal basis

The provisions governing the essential requirements and their operation are as follows:

• UK MDR 2002 (SI 2002/618, as amended): regulation 8 (essential requirements for general devices), regulation 9 (conformity with the relevant essential requirements), regulation 12 (exemptions from regulation 8 and regulation 10), regulation 22 (essential requirements for active implantable devices), regulation 23, regulation 34 (essential requirements for IVDs), regulation 35; and Schedule 2A (modifications to the annexes of Directives 93/42, 90/385 and 98/79).
• SI 2024/1368, regulation 3: amends the definition of relevant essential requirements in regulation 2(1).

The amendment by SI 2024/1368 is a reminder that even definitional provisions move: the meaning of relevant essential requirements is anchored in regulation 2(1) as amended, and any conformity file that predates the amendment should be checked against the current wording before it is reused.

3. Expert insights

Insight 1: the terminology difference forces real rework, not translation. Companies frequently take the EU MDR GSPR conformity table — the clause-by-clause mapping of Annex I — translate it into English and present it for the United Kingdom. The essential requirements in Great Britain differ from EU MDR Annex I in clause numbering and in parts of the wording, so a directly reused table is typically returned for rework during UKRP due diligence or MHRA data verification. The correct approach is to rebuild the table on the United Kingdom clause numbers and to re-map the evidence, which is less work than it sounds but far more than a find-and-replace.

Insight 2: the essential requirements and the exemption provisions must be read in pairs. Regulation 12 sets out exemptions from regulation 8 and regulation 10. Whether a device can invoke an exemption must be judged strictly against the specific circumstances that regulation 12 describes — the fact that a comparable exemption has been granted in another jurisdiction is not a reason. Exemption claims should be documented with the same care as conformity claims, because an undocumented exemption is indistinguishable, from the outside, from a requirement that was simply ignored.

Insight 3: the essential requirements are the feed-back target of post-market surveillance. The PMS system under Part 4A requires data to be used to update the technical documentation, including the risk analysis and the clinical evaluation. If the essential requirements conformity table is a static document that is not linked to PMS data, the arrangement constitutes a systemic deficiency under the new rules. The conformity table should therefore be treated as a living file: every surveillance cycle should ask whether new data changes the conformity position on any clause, and the answer should be recorded even when it is negative.

Taken together, these three points describe a single discipline: the essential requirements are not a static checklist satisfied once at certification, but a framework that terminology, exemptions and surveillance data continuously reshape. A conformity file that demonstrates compliance as of one date, under the wrong clause set and without exemption analysis, will not survive contact with the current system. The practical remedy is procedural rather than intellectual — assign the matrix an owner, give it a review calendar and make its update a precondition for closing each surveillance cycle, so that conformity evidence ages at the same pace as the product it describes.

4. Practical recommendations

GRZAN recommends preparing a dedicated essential requirements conformity matrix for the United Kingdom market, with the United Kingdom clause numbers as rows and the evidence files as columns, recording for each clause the applicability or inapplicability reasoning and the evidence source. The matrix should define annual review triggers aligned with the PMSR/PSUR preparation cycles, so that documentation refresh is scheduled by design rather than by memory. This prevents the compliance gap that emerges when a matrix sits unupdated for years: the technical file keeps changing, the conformity table does not, and the divergence is discovered only when a reviewer compares the two side by side.

When the matrix is first built, the most efficient sequence is to reuse the underlying evidence rather than the clause mapping from the European file. Test reports, risk analysis outputs and clinical evaluation conclusions usually remain valid; only their attachment to clause numbers needs redoing. Recording the European clause alongside the United Kingdom clause in the same row preserves traceability for audit purposes while making clear which numbering governs in Great Britain, and it gives reviewers a one-glance answer to the question they ask most often — where each claim of conformity comes from.

5. Verification checklist

• □ The essential requirements conformity matrix has been compiled on the United Kingdom clause numbers
• □ Whether regulation 12 exemptions can be invoked has been confirmed
• □ The matrix has been linked to a feed-back mechanism from PMS data
• □ Active implantable devices and IVDs have been mapped to regulation 22 / regulation 34 respectively
• □ Matrix versions and review records are traceable

Legal information verified as of 29 October 2026.

GRZAN supports manufacturers with the following services for the United Kingdom market:

• Appointment of the UK Responsible Person (UKRP) and signature support for the letter of authorisation
• End-to-end MHRA registration (DORS) filing and account lifecycle management
• Device classification determination, GMDN code selection and annual registration fee estimation
• Dual-track design for Great Britain and Northern Ireland, including UK(NI) solutions
• Post-market surveillance (PMS) system setup, PMSR/PSUR preparation and vigilance report submission
• Emergency response to serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory changes and compliance gap assessment

GRZAN provides end-to-end MHRA registration and compliance support for manufacturers entering the United Kingdom market, covering every stage from market entry planning through post-market obligations. For enquiries, contact info@grzanglobal.com.